Free tool
FAERS Monitor: Phendimetrazine Tartrate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018074 or its brand name (Phendimetrazine Tartrate, Phendimetrazine Tartrate). Reports on generic versions are filed under their own applications.
Reports
58
Serious
23
40% of reports
Hospitalization
8
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective9
- pain7
- headache6
- weight increased6
- back pain5
- wrong technique in product usage process5
- choroidal effusion4
- dyspnoea4
- fatigue4
- myopia4
- ocular hypertension4
- off label use4
- arthralgia3
- fall3
- hunger3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 3 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 6 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 7 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 8 |
| 2025 | 3 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,101 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| choroidal effusionSignal | 4 | 1817.3 | 704.1 | 5,531 |
| ocular hypertensionSignal | 4 | 748.8 | 290.6 | 2,282 |
| myopiaSignal | 4 | 610.3 | 236.9 | 1,859 |
| hungerSignal | 3 | 78.1 | 25.9 | 158 |
| weight increasedSignal | 6 | 9.7 | 4.6 | 39 |
| wrong technique in product usage processSignal | 5 | 8.9 | 3.9 | 28 |
| back painSignal | 5 | 7.8 | 3.4 | 24 |
| painSignal | 7 | 4.1 | 2.1 | 14 |
| headacheSignal | 6 | 3.5 | 1.6 | 8 |
| fall | 3 | 3.3 | 1.1 | 3 |
| arthralgia | 3 | 2.6 | 0.9 | 2 |
| dyspnoea | 4 | 2.6 | 1.0 | 2 |
| drug ineffectiveSignal | 9 | 2.5 | 1.4 | 7 |
| fatigue | 4 | 1.9 | 0.7 | 1 |
| off label use | 4 | 1.7 | 0.6 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.